OnKure Therapeutics, Inc. (OKUR)
| Market Cap | 212.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.52M |
| Shares Out | 40.40M |
| EPS (ttm) | -4.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,027 |
| Open | 4.97 |
| Previous Close | 4.99 |
| Day's Range | 4.97 - 5.28 |
| 52-Week Range | 1.70 - 5.28 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.00 (+414.29%) |
| Earnings Date | May 6, 2026 |
About OKUR
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for OKUR stock is "Strong Buy" and the 12-month stock price target is $27.0.
News
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and...
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations
OnKure Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key clinical data for OKI-219 in monotherapy, doublet, and triplet regimens are expected in Q1 2026, with a focus on demonstrating high tolerability and efficacy versus competitors. The pipeline includes a unique HER2-positive triplet and a pan-mutant program with strong selectivity benchmarks.
OnKure Therapeutics Transcript: Stifel 2025 Healthcare Conference
The presentation highlighted progress on highly selective PI3K alpha inhibitors, with OKI-219 advancing through monotherapy, doublet, and triplet studies in breast cancer. Key data on efficacy, safety, and combinability are expected in Q1 2026, guiding future development and competitive positioning.
OnKure Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
OKI-219, a highly selective PI3K alpha inhibitor, is advancing through monotherapy, doublet, and triplet clinical studies, with key data expected in Q1 2026. The compound's strong selectivity, CNS penetration, and favorable tolerability profile position it to compete in front-line breast cancer settings.
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patien...
OnKure Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today an...
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- I...
OnKure Therapeutics Transcript: AGM 2025
The meeting covered director elections and auditor ratification, confirmed a quorum, and provided a Q&A session. Both director nominees were elected and KPMG was ratified as auditor, with final results to be filed with the SEC.
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data
OnKure Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum
The session highlighted advances in PI3Kα mutant selective inhibitors, with OKI-219 showing promising early clinical data and a focus on high selectivity and tolerability. Combination studies are underway, and broader pipeline efforts target pan-mutant and helical domain mutations.
OnKure Therapeutics Transcript: Leerink's Global Healthcare Conference 2025
The discussion highlighted a focused strategy on PI3K alpha mutant selective therapies, with OKI-219 showing strong selectivity and tolerability in early trials. Key data readouts for monotherapy and combination studies are expected in the second half of the year.
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncol...
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported
OnKure Announces New Date for Upcoming Investor Call
Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT Investor call to review preliminary data from the PIKture-01 trial is now pla...
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET